Published in Gene Therapy Weekly, November 10th, 2005
According to recent research published in the journal Medical Science Monitor, "The aim of this study is to provide a basis for the design of appropriate protocols for the shipping and storage of rAAV vectors for experimental laboratory studies and clinical trials. Material rAAV stocks were generated by standard methods and then subjected to different environments. The transduction efficiency of viral vectors both in vitro and in vivo was determined by luciferase activity and immunohistochemistry."
"The virus stored at -80...
Want to see the full article?
Welcome to NewsRx!
Learn more about a six-week, no-risk free trial of Gene Therapy Weekly
Source: Gene Therapy Weekly (2005-11-10)
NewsRx also is available at LexisNexis, Gale, ProQuest, Factiva, Dialog, Thomson Reuters, NewsEdge, and Dow Jones.